The Neuropathy Daily
Everything New About Neuropathy Due to Benign and Malignant Disorders by Robert Z. Orlowski
Related Articles
Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma – PubMed
Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma
Predictive and Prognostic Significance of Patient-Reported Outcomes for Survival and Adverse Events in Daratumumab-Treated Multiple Myeloma – PubMed
Physical function is a predictive and prognostic marker that complements ECOG-PS, supporting its use in informing therapy decisions for daratumumab-based treatments.
Myeloma Paper of the Day, March 10th, suggested by Robert Orlowski – OncoDaily
Myeloma Paper of the Day, March 10th, suggested by Robert Orlowski / BCMA-negative myeloma, cancer, CAR-T therapy, Guixiang Wang, Jiahuan Chen, Jianqing Mi,
Myeloma cell intrinsic ANXA1 elevation and T cell dysfunction contribute to BCMA-negative relapse after CAR-T therapy – PubMed
Multiple myeloma (MM) relapse still occurs after a durable response to anti-BCMA chimeric antigen receptor-engineered T (CAR-T) cell therapy with less-defined factors. Herein, we investigated…
Myeloma Paper of the Day, March 9th, suggested by Robert Orlowski – OncoDaily
Myeloma Paper of the Day, March 9th, suggested by Robert Orlowski / cancer, Caroline Fidalgo Ribeiro, Eugenio Morelli, Massimo Loda, multiple myeloma, Myeloma
—–Targeting Acetyl-CoA Carboxylase Suppresses De Novo Lipogenesis and Tumor Cell Growth in Multiple Myeloma – PubMed
ACC1 is a metabolic vulnerability in MYC-driven MM. Inhibiting ACC1 disrupts lipid homeostasis, induces ER stress, and causes oxidative damage, impairing cell survival. Targeting lipid…
Targeting the RBM39-MEK5 axis synergizes with bortezomib to inhibit the malignant growth of multiple myeloma – PubMed
Aberrant alternative splicing is one of the hallmarks of cancer and is potentially based on upregulated expression of splicing factors in some types of cancer.…
Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody – PubMed
Chimeric antigen receptor (CAR) T cells and bispecific T cell engagers have become integral components in the treatment of relapsed/refractory multiple myeloma. We report a…
High WEE1 expression is independently linked to poor survival in multiple myeloma – PubMed
Current prognostic scores in multiple myeloma (MM) currently rely on disease burden and a limited set of genomic alterations. Some studies have suggested gene expression…